| breast cancer - HER2-positive | breast cancer - triple negative | ||
| es-BC - HER2 positive - (neo)adjuvant (NA) | mBC - Triple negative (TNBC) - 1st Line (L1) | es-BC - TNBC - NA - all population | |
| paclitaxel | |||
| nab-paclitaxel | FUTURE-SUPER_immunomodulatory subtype | GeparNuevo | |
| paclitaxel followed by doxorubicin plus cyclophosphamide | IMpassion-050 IMpassion-050 IMpassion-050 | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
